This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (54) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Daskalopoulou, S. S. Articles by Elisaf, M. Search for Related Content PubMed PubMed Citation Articles by Daskalopoulou, S. S. Articles by Elisaf, M. Social Bookmarking                   What's this?

Prevention and Treatment of the Metabolic Syndrome

Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital, London, UK

D. P. Mikhailidis, BSc, MSc, MD, FASA, FFPM, FRCP, FRCPath

Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital, London, UK

M. Elisaf, MD, FASA, FRSH

Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, egepi{at}cc.uoi.gr

The prevalence of the metabolic syndrome is increasing owing to lifestyle changes leading to obesity. This syndrome is a complex association of several interrelated abnormalities that increase the risk for cardiovascular disease and progression to diabetes mellitus (DM). Insulin resistance is the key factor for the clustering of risk factors characterizing the metabolic syndrome. The National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III defined the criteria for the diagnosis of the metabolic syndrome and established the basic principles for its management. According to these guidelines, treatment involves the improvement of the underlying insulin resistance through lifestyle modification (eg, weight reduction and increased physical activity) and possibly by drugs. The coexistent risk factors (mainly dyslipidemia and hypertension) should also be addressed. Since the main goal of lipid-lowering treatment is to achieve the NCEP low-density lipoprotein cholesterol (LDL-C) target, statins are a good option. However, fibrates (as monotherapy or in combination with statins) are useful for the treatment of the metabolic syndrome that is commonly associated with hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) levels. The blood pressure target is <140/90 mm Hg. The effect on carbohydrate homeostasis should possibly be taken into account in selecting an antihypertensive drug. Patients with the metabolic syndrome commonly have other less well-defined metabolic abnormalities (eg, hyperuricemia and raised C-reactive protein levels) that may also be associated with an increased cardiovascular risk. It seems appropriate to manage these abnormalities. Drugs that beneficially affect carbohydrate metabolism and delay or even prevent the onset of DM (eg, thiazolidinediones or acarbose) could be useful in patients with the metabolic syndrome. Furthermore, among the more speculative benefits of treatment are improved liver function in nonalcoholic fatty liver disease and a reduction in the risk of acute gout.

Angiology, Vol. 55, No. 6, 589-612 (2004)
DOI: 10.1177/00033197040550i601


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P Riley, J O'Donohue, and M Crook A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease J. Clin. Pathol., December 1, 2007; 60(12): 1384 - 1391. [Abstract] [Full Text] [PDF]

				R. S. Legro A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome JAMA, February 7, 2007; 297(5): 509 - 519. [Abstract] [Full Text] [PDF]